Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arcus Biosciences (RCUS)

Arcus Biosciences Q4 Revenue Rises to $36 Million; Full-Year Loss Narrows

Positive Impact 3 of 5 earnings Written later

Arcus Biosciences reported fourth-quarter and full-year 2024 results. Full-year revenue rose to $258 million from $117 million and the net loss narrowed to $283 million from $307 million, or $3.14 per share versus $4.15. The company ended the year with $992 million in cash, cash equivalents and marketable securities after completing a $150 million financing, though fourth-quarter net loss widened to $94 million from $81 million.

Key points

  • Full-year 2024 revenue was $258 million, compared with $117 million in 2023
  • Full-year net loss per share was $3.14, compared with $4.15 in 2023; full-year R&D expenses were $448 million, compared with $340 million
  • Fourth-quarter 2024 net loss was $94 million, compared with $81 million, on revenue of $36 million versus $31 million
  • Cash, cash equivalents and marketable securities were $992 million as of December 31, 2024, excluding proceeds from the $150 million financing

The filing

CompanyArcus Biosciences (RCUS)
Form8-K, current report
Filed with the SECFeb 25, 2025, 4:07 PM ET
Accession number0001724521-25-000039

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:49 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 25, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.